Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-17 12:34 pm Sale | 2025-12-31 | 13G | Akero Therapeutics, Inc. AKRO | JANUS HENDERSON GROUP PLC JHG | 3,397,779 4.100% | -2,882,526 (-45.90%) | Filing History |
| 2026-02-17 08:20 am Sale | 2025-12-31 | 13G | Akero Therapeutics, Inc. AKRO | RTW Investments, LP | 0 0.000% | -5,873,308 (Position Closed) | Filing History |
| 2026-02-13 08:41 am Sale | 2025-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Deep Track Capital, LP | 0 0.000% | -4,400,000 (Position Closed) | Filing History |
| 2026-02-10 11:23 am Sale | 2025-12-31 | 13G | Akero Therapeutics, Inc. AKRO | WELLINGTON MANAGEMENT GROUP LLP | 0 0.000% | -4,251,861 (Position Closed) | Filing History |
| 2025-11-14 12:19 pm Purchase | 2025-09-30 | 13G | Akero Therapeutics, Inc. AKRO | T. Rowe Price Associates, Inc. | 3,810,076 4.800% | 1,717 (+0.05%) | Filing History |
| 2025-11-14 12:07 pm Sale | 2025-09-30 | 13G | Akero Therapeutics, Inc. AKRO | JANUS HENDERSON GROUP PLC JHG | 6,280,305 7.900% | -458,251 (-6.80%) | Filing History |
| 2025-11-12 09:33 am Purchase | 2025-09-30 | 13G | Akero Therapeutics, Inc. AKRO | WELLINGTON MANAGEMENT GROUP LLP | 4,251,861 5.300% | 841,915 (+24.69%) | Filing History |
| 2025-10-07 4:34 pm Purchase | 2025-09-30 | 13G | Akero Therapeutics, Inc. AKRO | Deep Track Capital, LP | 4,400,000 5.500% | 4,400,000 (New Position) | Filing History |
| 2025-08-14 11:25 am Sale | 2025-06-30 | 13G | Akero Therapeutics, Inc. AKRO | JANUS HENDERSON GROUP PLC JHG | 6,738,556 8.500% | -330,438 (-4.67%) | Filing History |
| 2025-08-14 08:00 am Sale | 2025-06-30 | 13G | Akero Therapeutics, Inc. AKRO | RTW Investments, LP | 5,873,308 7.300% | -986,515 (-14.38%) | Filing History |
| 2025-08-12 10:34 am Sale | 2025-06-30 | 13G | Akero Therapeutics, Inc. AKRO | WELLINGTON MANAGEMENT GROUP LLP | 3,409,946 4.300% | -2,526,294 (-42.56%) | Filing History |
| 2025-05-15 08:13 am Purchase | 2025-03-31 | 13G | Akero Therapeutics, Inc. AKRO | GENERAL ATLANTIC, L.P. | 6,796,489 8.400% | 1,562,500 (+29.85%) | Filing History |
| 2025-05-14 12:24 pm Purchase | 2025-03-31 | 13G | Akero Therapeutics, Inc. AKRO | JANUS HENDERSON GROUP PLC JHG | 7,068,994 8.900% | 1,034,755 (+17.15%) | Filing History |
| 2025-05-12 10:44 am Sale | 2025-03-31 | 13G | Akero Therapeutics, Inc. AKRO | WELLINGTON MANAGEMENT GROUP LLP | 5,936,240 7.500% | -1,960,392 (-24.83%) | Filing History |
| 2025-02-14 12:58 pm Sale | 2024-12-31 | 13G | Akero Therapeutics, Inc. AKRO | JANUS HENDERSON GROUP PLC JHG | 6,034,239 8.700% | -1,043,239 (-14.74%) | Filing History |
| 2025-02-14 09:00 am Purchase | 2024-12-31 | 13G | Akero Therapeutics, Inc. AKRO | RTW Investments, LP | 6,859,823 9.800% | 940,388 (+15.89%) | Filing History |
| 2024-11-14 3:59 pm Purchase | 2024-09-30 | 13G | Akero Therapeutics, Inc. AKRO | JANUS HENDERSON GROUP PLC JHG | 7,077,478 10.200% | 127,060 (+1.83%) | Filing History |
| 2024-11-14 1:22 pm Purchase | 2024-09-30 | 13G | Akero Therapeutics, Inc. AKRO | T. Rowe Price Associates, Inc. | 3,808,359 5.500% | 127,150 (+3.45%) | Filing History |
| 2024-11-14 06:51 am Purchase | 2024-09-30 | 13G | Akero Therapeutics, Inc. AKRO | RTW Investments, LP | 5,919,435 8.500% | 2,326,676 (+64.76%) | Filing History |
| 2024-11-13 09:45 am Sale | 2024-09-30 | 13G | Akero Therapeutics, Inc. AKRO | Alkeon Capital Management LLC | 3,325,004 4.800% | -439,216 (-11.67%) | Filing History |